A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
Authors
Keywords
-
Journal
BMC Pulmonary Medicine
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-17
DOI
10.1186/s12890-021-01490-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
- (2020) Man-Hong Leung et al. Cancers
- Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
- (2020) Andrea Sartore-Bianchi et al. Expert Review of Anticancer Therapy
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Personalized Medicine: Recent Progress in Cancer Therapy
- (2020) Valentina Gambardella et al. Cancers
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
- (2017) Tawee Tanvetyanon et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
- (2017) Jody C. Chuang et al. Journal of Thoracic Oncology
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
- (2015) Mariacarmela Santarpia et al. Expert Review of Clinical Pharmacology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now